Skylar Jeremias

A real-world analysis found that comprehensive genomic profiling (CGP) in patients with non–small cell lung cancer (NSCLC) increases their therapy options patients and CGP testing needs to be utilized more.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Amy Valley, PharmD, vice president of clinical strategy and technology solutions, Cardinal Health Specialty Solutions, discusses the Decision Path, a clinical support tool designed to inform oncology providers about drug costs along with clinical information, all embedded into the electronic health record workflow.

A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.

Posters from the American Association of Cancer Research (AACR) Annual Meeting demonstrated the use of genomic profiling and sequencing can detect immunotherapy biomarkers and predict clinical outcomes in patients with cancer.

A panel of providers and patients with narcolepsy who are parents shared the struggles and possible support tools that neurologists and other providers should be aware of when caring for patients with narcolepsy who are pregnant or postpartum.

During her presentation at SLEEP 2022, Isabelle Arnulf, MD, PhD, a neurologist and professor, detailed the long list of challenges for understanding different aspects of idiopathic hypersomnia and called for more attention to be devoted to future research.

Presenters from SLEEP 2022 contextualized some of the recent research showing the impact of sleep disorders on aspects of mental health, including depressive symptoms and suicide.

Susan Redline, MD, MPH, the SLEEP 2022 meeting keynote speaker, catalogued the evidence proving that continuous positive airway pressure (CPAP) does improve health outcomes—refuting a recent controversial report that claims otherwise.

A panel of experts at the SLEEP 2022 conference argued against considering race a risk factor for health complications and disrupted sleep, saying that being on the receiving end of racial discrimination is the true risk factor.

Posters from the SLEEP 2022 conference revealed some of the interaction between idiopathic hypersomnia and different aspects of life, including weight changes and interpersonal relationships.

Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council (NPC), explains the ways that the gene therapy market is working to address concerns regarding contractual riders for value-based contracts for expensive therapies.

The FDA approval for Fylnetra represents the fifth approval for a biosimilar referencing Neulasta (pegfilgrastim) in the United States.

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, describes the lasting equity concerns regarding the use of health technology assessments (HTAs) for women.

Soumya Vishwanath, PharmD, senior manager of formulary management at Magellan Rx Management, explained what she wishes more people understood about digital therapeutics for behavioral health disorders.

Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, explained the importance of taking multiple factors into consideration when making health care decisions.

Marking Women's Health Month, Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, detailed how value assessments can address health care imbalances for women.

Black, Asian, and Hispanic adults in the United States were found to have an increased risk for developing diabetes at lower weights and younger ages compared with White Americans, suggesting that screening recommendations for the disease should be altered to reflect this difference.

Health plans and payers have plenty of options for how to analyze the effectiveness of digital therapeutic tools, as there are several effective strategies, according to Soumya Vishwanath, PharmD, of Magellan Rx Management.

Sharon Phares, PhD, MPH, discussed her new appointment as the chief scientific officer of the National Pharmaceutical Council (NPC) and her main priorities in honor of Women's Health Month.

Although crowdfunding can be a financial lifeline for young adult patients with serious medical conditions, the nuances regarding the need for and the long-term impact of crowdfunding exposes a facet of the US health care system that must be addressed.

Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.

Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.

Michael Ciarametaro, MBA, vice president of research at the National Pharmaceutical Council, highlights steps clinics can take to mitigate issues related to data collection regarding cell and gene therapies.

Researchers found that implementing an incremental schedule for hemodialysis in patients with residual kidney disease produced similar clinical outcomes and significant savings for health systems compared with hemodialysis administered on a more traditional schedule.

Despite technological advancements, there are still many factors that can cause specimens for comprehensive genomic profiling (CGP) testing to become compromised, potentially leading to inaccurate prognostic results, according to a recent webinar.

Flow–minimal residual disease (MRD) assessment in patients with multiple myeloma (MM) was found to be a good tool for early detection of MRD and could aid providers in treatment decision-making.

A literature review outlined the number of fertility complications that men and women with chronic kidney disease (CKD) face as well as the list of potential factors that can impact fertility and sexual functions in this population.

A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.